KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Outstanding (Diluted Average): 2010-2024

Historic Shares Outstanding (Diluted Average) for Regeneron Pharmaceuticals (REGN) over the last 15 years, with Dec 2024 value amounting to $115.1 million.

  • Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) fell 6.28% to $108.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.9 million, marking a year-over-year decrease of 6.28%. This contributed to the annual value of $115.1 million for FY2024, which is 1.23% up from last year.
  • According to the latest figures from FY2024, Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) is $115.1 million, which was up 1.23% from $113.7 million recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $115.1 million during FY2020, and registered a low of $112.2 million during FY2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $113.7 million (2023), whereas its average is $114.1 million.
  • Per our database at Business Quant, Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) declined by 2.52% in 2021 and then grew by 1.23% in 2024.
  • Over the past 5 years, Regeneron Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $115.1 million in 2020, then dropped by 2.52% to $112.2 million in 2021, then climbed by 1.16% to $113.5 million in 2022, then increased by 0.18% to $113.7 million in 2023, then climbed by 1.23% to $115.1 million in 2024.